Valuation: Positron Corporation

Market Cap 5.65Cr 4.88Cr 4.58Cr 4.17Cr 7.84Cr 540.16Cr 7.94Cr 54Cr 21Cr 270.62Cr 21Cr 21Cr 900.2Cr P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 5.54Cr 4.78Cr 4.48Cr 4.08Cr 7.68Cr 529.3Cr 7.79Cr 53Cr 21Cr 265.18Cr 21Cr 20Cr 882.1Cr EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
1 day+2.15%
1 week+18.38%
Current month+7.83%
1 month+15.15%
3 months-2.31%
6 months+1.06%
Current year+13.77%
1 week 1.64
Extreme 1.64
1.91
1 month 1.45
Extreme 1.45
1.91
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+18.38%+4.40%+38.20% 5.65Cr
-0.55%-4.35%-15.75%-18.75% 1.31TCr
+2.62%+10.27%+46.61%+17.55% 464.03Cr
-0.68%+0.49%-40.30%-51.96% 129.51Cr
-0.26%+21.69%-32.27% - 119.77Cr
+0.09%-1.04%-35.21%-37.86% 118.79Cr
+1.23%-2.49%+25.06%+81.00% 112.55Cr
-0.24%-3.47%+42.76%+144.12% 59Cr
-0.23%-3.52%+67.40% - 32Cr
+1.93%-1.22%-62.43%+299.79% 25Cr
Average +0.61%+1.33%+0.03%+59.01% 237.86Cr
Weighted average by Cap. +0.24%+0.58%-2.65%-0.99%

Financials

2024 2025
Net sales 6L 5L 5L 4L 8L 5.62Cr 8L 55.78L 21.86L 2.81Cr 22.06L 21.58L 9.36Cr 5L 4L 4L 3L 6L 4.41Cr 6L 43.81L 17.17L 2.21Cr 17.32L 16.95L 7.35Cr
Net income -23.79L -20.54L -19.27L -17.55L -33L -23Cr -33.46L -2.26Cr -88.51L -11Cr -89.32L -87.39L -38Cr -1.06Cr -91.54L -85.88L -78.22L -1.47Cr -101.38Cr -1.49Cr -10Cr -3.94Cr -51Cr -3.98Cr -3.89Cr -168.96Cr
Net Debt 14.24L 12.3L 11.54L 10.51L 19.76L 14Cr 20.03L 1.35Cr 53L 6.82Cr 53.48L 52.32L 23Cr -11.36L -10L -9L -8L -15.76L -11Cr -15.98L -1.08Cr -42.27L -5.44Cr -42.66L -41.73L -18Cr
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
17/26/17 $1.720 -4.99% 3,446
14/26/14 $1.810 +4.04% 6,600
13/26/13 $1.740 -3.87% 39,687
12/26/12 $1.810 +13.12% 40,674
11/26/11 $1.600 -0.31% 38,922
  1. Stock Market
  2. Stocks
  3. POSC Stock